cancer profiling, diagnostics
new antibiotics class
Optimum is an international strategic healthcare communications firm, specialising in investor relations, corporate and financial communications. Our team of healthcare specialists, based in London and New York, have worked together for many years. We are experienced and trusted advisors to some of the world's most exciting public and private companies across pharmaceuticals, medtech, biotech, digital health and healthcare services, large and small.
Watch our Member Showcase Video https://bit.ly/3FFKIIz
Watch our Member Showcase Video https://bit.ly/3FFKIIz
Our Biosciences Team has advised on a wide variety of matters including research and development agreements, patent and know how licences and assignments, manufacturing agreements, bioinformatics, regulatory matters, clinical trials, patent litigation and competition law. The members of the Biosciences Team pride themselves on their responsive, hands-on and pro-active approach. This includes helping to find venture capital finance for clients through the firm's extensive corporate finance network and advising on intellectual property protection and exploitation. Osborne Clarke recognises that biotechnology companies want to deal with a team of specialists whose experience ensures technically accurate and commercial, pragmatic advice.. . Biotechnology agreements, collaborations, research and devleopment agreements, venture capital and other funding arrangements for biotechnology companies. Represented in most major European jurisdictions and in Silicon Valley.. . Bioinformatics, law, European law, research, colllaboration, contract research, intellectual property, patents, financing, competition law, technology transfer, mergers and acquisitions, due diligence, regulatory matters.
No data available
Ovartix is a women’s health drug discovery company that harnesses large-scale human multi-omics data, state-of-the-art cell engineered and animal models to identify, validate and develop next-generation therapeutics for ovary-centric female reproductive disorders, such as infertility and menopause
Sustainable bio-based materials for fashion
Spun out from the Karolinska Institute in 2013, Pelago Bioscience AB was founded by the inventors of the Cellular Thermal Shift Assay (CETSA®) to both develop the method and to provide a commercial service for organisations wanting to use the method.. . CETSA measures compound binding under actual physiological conditions within either a cellular of lysate environment. The assay relies on a well-established observation that compound binding with a protein will change its thermal denaturation point, meaning that at a given denaturation temperature there will be a difference in the abundance of the intact protein as compared with a negative control. It is the only technique that will confirm such target engagement is occurring and provides ‘real world’ EC50 values for your compound in cells.. . The company controls the patents on CETSA and delivers in situ target engagement studies to accelerate preclinical and clinical drug discovery and diagnostics development. Using CETSA data and applications, drug discovery R&D companies are able to make better and more informed decisions at earlier stages in their projects.
Pharma International provides global pharmaceutical regulatory consultancy services, with an emphasis on the emerging markets. Fully licensed by Swissmedic, Pharma International is authorised to trade in biotechnology, pharmaceuticals and medical devices internationally – as well as providing Swiss Qualified Person services. Seminars on regulatory affairs, especially Asia including ASEAN, China, Korea and India, are conducted regularly and can be adapted to in-house requirements.
Regulatory Consultancy